Skip to main content

Thrombosed AV grafts

Arteriovenous (AV) access grafts that have thrombosed are often associated with worse outcomes than those that are stenosed1

  • The 2006 KDOQI guidelines for vascular access specify reasonable goals as follows2:
    • Stenosed grafts: 50% primary patency at six months 
    • Thrombosed grafts: 40% primary patency at three months

There are a limited number of randomized trials to help guide evidence-based treatment decisions for patients with thrombosed grafts

  • In the Gore REVISE Clinical Study, 43% of patients in the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface* arm of the study enrolled with a thrombosed graft.

The GORE® VIABAHN® Device has proven success when treating thrombosed grafts1,2 

Proven patency

  • Exceeded KDOQI minimum guidelines for three-month circuit primary patency for thrombotic patients (48%) whereas Percutaneous Transluminal Angioplasty (PTA) did not (39%)1,2
  • Increased primary patency in thrombosed grafts of both the target lesion and the circuit by ~50% when compared to PTA at six months1

Fewer reinterventions

  • Lowered the mean number of interventions over two years by 40% in thrombosed grafts3

* As used by Gore, PROPATEN Bioactive Surface refers to Gore’s proprietary CBAS® Heparin Surface.

  1. Vesely T, DaVanzo W, Behrend T, Dwyer A, Aruny J. Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts. Journal of Vascular Surgery 2016;64(5):1400-1410.e1.
  2. Kidney Disease Outcomes, Quality Initiative (KDOQI). Clinical Practice Guidelines and Clinical Practice Recommendations. 2006 Updates. National Kidney Foundation Web site. . Accessed July 17, 2018.
  3. Mohr BA, Sheen AL, Roy-Chaudhury P, Schultz SR, Aruny JE; REVISE Investigators.  Clinical and economic benefits of stent grafts in dysfunctional and thrombosed hemodialysis access graft circuits in the REVISE Randomized Trial.  Journal of Vascular & Interventional Radiology 2019;30(2):203-211.e4.

eIFU Symbol

Refer to Instructions for Use at for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly